Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shanghai Schering-Plough Pharmaceutical To Transfer 45 Percent Stock

This article was originally published in PharmAsia News

Executive Summary

Shanghai Schering-Plough Pharmaceutical, a joint venture 55 percent owned by Schering-Plough (China) Ltd., recently listed 45 percent of its equity-30 percent owned by Shanghai Pharmaceutical Industry Co. and 15 percent by Shanghai Pharmaceutical (Group)-on Shanghai United Assets and Equity Exchange for 66.329 million yuan (9.5 million). The two Chinese partners' pullout paves the way for Schering-Plough (China) to gain full control of Shanghai Schering-Plough Pharmaceutical; according to transfer terms, the foreign MNC has first rights to bid for the shares. Shanghai Schering-Plough Pharmaceutical has to defer to the policies of majority shareholder Schering-Plough (China) for its supplies and product export; thus any third-party deal will need the latter's blessings. (Click here for more - Chinese Language)

You may also be interested in...



Schering Plough To Buy Out Shanghai Partners

BEIJING - Schering Plough's Chinese partners are selling all their stakes in the joint venture in Shanghai and Schering Plough plans to buy them out to begin wholly owned operations in China next year

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel